SCYX News
Archived Headlines
- 4 US IPOs planned for the week of Apr 28 04/28/14
- 4 US IPOs planned for the week of Apr 21 04/21/14
- 16 US IPOs planned for the week of Apr 7 04/07/14
- SCYNEXIS increases shares offered and drops its range to $7 to $8 04/02/14
- 8 US IPOs planned for the week of Mar 31 03/31/14
See more
Fungus fighter Cidara Therapeutics sets terms for $60 million IPO
Cidara Therapeutics, which is developing novel therapies for fungal infections, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 to $16. At the midpoint...read more
Fungus beware: Cidara Therapeutics files for a $69 million IPO
Cidara Therapeutics, which is developing novel therapies for fungal infections, filed on Friday with the SEC to raise up to $69 million in an initial public offering. Last year's antifungal biotech SCYNEXIS (SCYX) trades at about its offer price. The...read more
SCYNEXIS prices IPO at $10, as expected
SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, raised $62 million by offering 6.2 million shares at $10, as expected. SCYNEXIS plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity acted...read more
SCYNEXIS increases deal size to $62 million but slashes market cap
SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, raised the proposed deal size for its upcoming IPO on Wednesday. The Durham, NC-based company now plans to raise $62 million by offering 6.2 million shares at $10 per share. The...read more